76.49
price up icon0.95%   0.72
pre-market  Pre-market:  72.47   -4.02   -5.26%
loading
Hologic Inc stock is currently priced at $76.49, with a 24-hour trading volume of 1.43M. It has seen a +0.95% increased in the last 24 hours and a +4.92% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $75.38 pivot point. If it approaches the $76.66 resistance level, significant changes may occur.
Previous Close:
$75.77
Open:
$75.86
24h Volume:
1.43M
Market Cap:
$17.85B
Revenue:
$3.96B
Net Income/Loss:
$466.50M
P/E Ratio:
39.63
EPS:
1.93
Net Cash Flow:
$948.90M
1W Performance:
+4.10%
1M Performance:
+4.92%
6M Performance:
+5.61%
1Y Performance:
-3.29%
1D Range:
Value
$75.81
$76.75
52W Range:
Value
$64.02
$82.45

Hologic Inc Stock (HOLX) Company Profile

Name
Name
Hologic Inc
Name
Phone
(508) 263-2900
Name
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Name
Employee
6,990
Name
Twitter
@Hologic
Name
Next Earnings Date
2024-06-04
Name
Latest SEC Filings
Name
HOLX's Discussions on Twitter

Hologic Inc Stock (HOLX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-14-23 Upgrade Needham Hold → Buy
Dec-07-22 Initiated RBC Capital Mkts Sector Perform
Oct-13-22 Initiated Mizuho Buy
Jul-20-22 Downgrade BofA Securities Buy → Neutral
Jul-20-22 Initiated UBS Neutral
Jul-18-22 Downgrade BTIG Research Buy → Neutral
Apr-25-22 Downgrade Wells Fargo Overweight → Equal Weight
Apr-04-22 Downgrade Evercore ISI Outperform → In-line
Dec-15-21 Downgrade Citigroup Buy → Neutral
Oct-15-21 Resumed Cowen Outperform
Oct-14-21 Initiated Redburn Neutral
Jul-06-21 Upgrade Evercore ISI In-line → Outperform
Nov-20-20 Downgrade Needham Buy → Hold
Nov-05-20 Reiterated Needham Buy
Jun-30-20 Upgrade Cowen Market Perform → Outperform
Jun-03-20 Upgrade Raymond James Mkt Perform → Outperform
Apr-30-20 Reiterated Needham Buy
Apr-30-20 Upgrade SVB Leerink Mkt Perform → Outperform
Apr-07-20 Upgrade Wells Fargo Equal Weight → Overweight
Mar-27-20 Upgrade Morgan Stanley Underweight → Equal-Weight
Jan-13-20 Reiterated Needham Buy
Jan-08-20 Initiated Wells Fargo Equal Weight
Jan-07-20 Initiated Citigroup Buy
Jan-02-20 Downgrade Evercore ISI Outperform → In-line
Sep-26-19 Upgrade BofA/Merrill Neutral → Buy
Aug-01-19 Reiterated Needham Buy
May-02-19 Reiterated Needham Buy
Jan-31-19 Reiterated Needham Buy
Jan-02-19 Downgrade Morgan Stanley Equal-Weight → Underweight
Oct-09-18 Initiated UBS Neutral
Sep-13-18 Downgrade BofA/Merrill Buy → Neutral
View All

Hologic Inc Stock (HOLX) Financials Data

Hologic Inc (HOLX) Revenue 2024

HOLX reported a revenue (TTM) of $3.96 billion for the quarter ending March 31, 2024, a -2.37% decline year-over-year.
loading

Hologic Inc (HOLX) Net Income 2024

HOLX net income (TTM) was $466.50 million for the quarter ending March 31, 2024, a -38.05% decrease year-over-year.
loading

Hologic Inc (HOLX) Cash Flow 2024

HOLX recorded a free cash flow (TTM) of $948.90 million for the quarter ending March 31, 2024, a +12.90% increase year-over-year.
loading

Hologic Inc (HOLX) Earnings per Share 2024

HOLX earnings per share (TTM) was $1.96 for the quarter ending March 31, 2024, a -34.45% decline year-over-year.
loading

Hologic Inc Stock (HOLX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
GARRETT SCOTT T
Director
Mar 14 '24
Option Exercise
30.93
16,441
508,471
65,052
GARRETT SCOTT T
Director
Mar 14 '24
Sale
75.50
16,441
1,241,296
48,611
CRAWFORD SALLY
Director
Mar 08 '24
Option Exercise
26.74
9,039
241,703
141,966
CRAWFORD SALLY
Director
Mar 08 '24
Sale
76.40
9,039
690,607
132,927
Dockendorff Charles J
Director
Mar 08 '24
Sale
76.21
1,465
111,648
1,572
Oberton Karleen Marie
Chief Financial Officer
Jan 29 '24
Sale
75.00
14,940
1,120,500
103,916
Dockendorff Charles J
Director
Jan 02 '24
Option Exercise
38.44
7,551
290,260
17,482
Dockendorff Charles J
Director
Jan 02 '24
Sale
72.00
16,017
1,153,224
1,465
GARRETT SCOTT T
Director
Dec 11 '23
Sale
68.71
10,000
687,116
47,039
MACMILLAN STEPHEN P
Chairman, President and CEO
Nov 29 '23
Option Exercise
26.21
47,711
1,250,505
1,286,799
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
medical_instruments_supplies BAX
$35.22
price up icon 2.83%
medical_instruments_supplies COO
$88.58
price up icon 3.54%
medical_instruments_supplies WST
$333.30
price up icon 3.72%
medical_instruments_supplies TFX
$224.48
price up icon 1.77%
medical_instruments_supplies ATR
$142.09
price up icon 0.57%
Cap:     |  Volume (24h):